Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) announced it has executed a term sheet with arm’s-length institutional investors for a previously announced non-brokered private placement with a notional subscription amount of approximately CAD$5 million. The offering will consist of 6,764,070 units at a notional price of CAD$0.7392 per unit, with each unit comprising one common share and one common share purchase warrant. The placement is expected to close on or about July 15, 2026, subject to customary conditions and regulatory approvals.
The company said proceeds from the financing are intended to support development of its ONC010 program, including manufacturing and preclinical testing activities, advancement of its SynoGraph(TM) platform and general working capital. Under the proposed structure, the company’s economic interest will be determined through 18 monthly settlement tranches based on the future trading price of its shares, with additional details to be provided upon closing.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. Onco has secured an exclusive worldwide license to patented technology that targets solid tumours.
The full press release is available at https://ibn.fm/y3hsM.
This announcement is significant as it provides Onco-Innovations with the necessary capital to advance its oncology pipeline, particularly the ONC010 program and SynoGraph platform, which could lead to new cancer treatment options. The involvement of institutional investors signals confidence in the company’s technology and future prospects.
For the latest news and updates relating to ONNVF, visit the company’s newsroom at https://ibn.fm/ONNVF.
